These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
78 related articles for article (PubMed ID: 1674933)
1. Ovarian stimulation concomitant with pituitary-ovarian axis suppression by different GnRH agonists. Insler V; Lunenfeld E; Potashnik G; Levy J Int J Fertil; 1991; 36(2):121-7. PubMed ID: 1674933 [TBL] [Abstract][Full Text] [Related]
2. The effect of different LH-RH agonists on the levels of immunoreactive gonadotropins. Insler V; Lunenfeld E; Potashnik G; Levy J Gynecol Endocrinol; 1988 Dec; 2(4):305-12. PubMed ID: 2976572 [TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of low dose hCG for luteal support after triggering ovulation with a GnRH agonist in cases of polyfollicular development. Krause BT; Ohlinger R Eur J Obstet Gynecol Reprod Biol; 2006 May; 126(1):87-92. PubMed ID: 16377065 [TBL] [Abstract][Full Text] [Related]
4. Effects of pretreatment with an oral contraceptive on the time required to achieve pituitary suppression with gonadotropin-releasing hormone analogues and on subsequent implantation and pregnancy rates. Biljan MM; Mahutte NG; Dean N; Hemmings R; Bissonnette F; Tan SL Fertil Steril; 1998 Dec; 70(6):1063-9. PubMed ID: 9848296 [TBL] [Abstract][Full Text] [Related]
5. A preliminary study on reduced dose (33 or 25 microg) gonadotropin-releasing hormone agonist long protocol for multifollicular ovarian stimulation in patients with high basal serum follicle-stimulating hormone levels undergoing in vitro fertilization-embryo transfer. Ku SY; Choi YS; Jee BC; Suh CS; Choi YM; Kim JG; Moon SY; Kim SH Gynecol Endocrinol; 2005 Oct; 21(4):227-31. PubMed ID: 16316845 [TBL] [Abstract][Full Text] [Related]
6. The use of long-acting gonadotropin-releasing hormone agonist (GnRH-a; decapeptyl) and gonadotropins versus short-acting GnRH-a (buserelin) and gonadotropins before and during ovarian stimulation for in vitro fertilization (IVF). Gonen Y; Dirnfeld M; Goldman S; Koifman M; Abramovici H J In Vitro Fert Embryo Transf; 1991 Oct; 8(5):254-9. PubMed ID: 1836810 [TBL] [Abstract][Full Text] [Related]
7. Serum luteinizing hormone, follicle-stimulating hormone and oestradiol pattern in women undergoing pituitary suppression with different gonadotrophin-releasing hormone analogue protocols for assisted reproduction. Manna C; Rahman A; Sbracia M; Pappalardo S; Mohamed EI; Linder R; Nardo LG Gynecol Endocrinol; 2005 Apr; 20(4):188-94. PubMed ID: 16019360 [TBL] [Abstract][Full Text] [Related]
8. Triggering ovulation with gonadotropin-releasing hormone agonists does not compromise embryo implantation rates. Acevedo B; Gomez-Palomares JL; Ricciarelli E; Hernández ER Fertil Steril; 2006 Dec; 86(6):1682-7. PubMed ID: 17074344 [TBL] [Abstract][Full Text] [Related]
9. Role of gonadotropin releasing hormone agonists in ovulation induction. Dodson WC J Reprod Med; 1989 Jan; 34(1 Suppl):76-80. PubMed ID: 2497247 [TBL] [Abstract][Full Text] [Related]
10. GnRH analogs: depot versus short formulations. Dal Prato L; Borini A; Cattoli M; Bonu MA; Sereni E; Flamigni C Eur J Obstet Gynecol Reprod Biol; 2004 Jul; 115 Suppl 1():S40-3. PubMed ID: 15196715 [TBL] [Abstract][Full Text] [Related]
11. Adjunctive leuprolide therapy does not improve cycle fecundity in controlled ovarian hyperstimulation and intrauterine insemination of subfertile women. Dodson WC; Walmer DK; Hughes CL; Yancy SE; Haney AF Obstet Gynecol; 1991 Aug; 78(2):187-90. PubMed ID: 1906152 [TBL] [Abstract][Full Text] [Related]
12. [GnRH agonists in the ovulation stimulation scheme for in vitro fertilization]. Roztocil A; Pilka L; Holubová M Cesk Gynekol; 1989 Dec; 54(10):776-82. PubMed ID: 2534286 [No Abstract] [Full Text] [Related]
13. The serum follicle-stimulating hormone-to-luteinizing hormone ratio at the start of stimulation with gonadotropins after pituitary down-regulation is inversely correlated with a mature oocyte yield and can predict "low responders". Ho JY; Guu HF; Yi YC; Chen MJ; Ho ES Fertil Steril; 2005 Apr; 83(4):883-8. PubMed ID: 15820795 [TBL] [Abstract][Full Text] [Related]
14. Beneficial effect of luteal-phase GnRH agonist administration on embryo implantation after ICSI in both GnRH agonist- and antagonist-treated ovarian stimulation cycles. Tesarik J; Hazout A; Mendoza-Tesarik R; Mendoza N; Mendoza C Hum Reprod; 2006 Oct; 21(10):2572-9. PubMed ID: 16926261 [TBL] [Abstract][Full Text] [Related]
15. Endocrine profiles and luteal function during GnRH-analogue/HMG therapy. Braendle W; Lindner C; Lichtenberg V; Goepel E; Bettendorf G Hum Reprod; 1989 Nov; 4(8 Suppl):121-6. PubMed ID: 2533217 [TBL] [Abstract][Full Text] [Related]
16. Induction of ovulation with pulsatile gonadotropin releasing hormone (GnRH) in anovulatory women. Cignitti M; Mazzarini A; Pini A; Garzetti GG; Romanini C Acta Eur Fertil; 1990; 21(5):235-8. PubMed ID: 2132474 [TBL] [Abstract][Full Text] [Related]
17. Suppression with gonadotropin-releasing hormone analogues prior to stimulation with gonadotropins: comparison of three protocols. Lipitz S; Ben-Rafael Z; Dor J; Shalev J; Elenbogen A; Levran D; Serr DM; Mashiach S Gynecol Obstet Invest; 1989; 28(1):31-4. PubMed ID: 2528497 [TBL] [Abstract][Full Text] [Related]
18. Oral contraceptive therapy for polycystic ovary disease after chronic gonadotropin-releasing agonist administration. Predictors of continued ovarian suppression. Elkind-Hirsch KE; Anania C; Malinak R J Reprod Med; 1996 Sep; 41(9):645-52. PubMed ID: 8887188 [TBL] [Abstract][Full Text] [Related]